HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in adults with HIV-1 through 24 weeks, according to a phase IIb study. Among ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...

Topline results were announced from two phase 3 trials evaluating doravirine/islatravir (DOR/ISL) in adults with virologically-suppressed HIV-1 infection. The investigational therapy combines ...

The US Food and Drug Administration (FDA) has stopped trials of oral and implant formulations of islatravir for HIV, the investigational drug's developer, Merck and Co, announced in a press release.

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591 ...

Concerns about lower lymphocyte levels in HIV with the once-daily oral drug islatravir in combination with doravirine changed the trajectory of clinical trial plans that are now back on track, ...

Doravirine/islatravir would be the first FDA-approved two-drug regimen without an integrase inhibitor that demonstrated non-inferior efficacy and a generally comparable safety profile to the ...

The table below is a review of notable updates that occurred in November 2025 for investigational products in development (not an inclusive list). Click on the status ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...